Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Kevin C J, Yuen"'
Publikováno v:
BMC Medical Education, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Hypopituitarism, including growth hormone deficiency (GHD), is a common sequela of traumatic brain injury (TBI). This study explored the coverage of education and training of TBI-induced hypopituitarism in general and GHD in parti
Externí odkaz:
https://doaj.org/article/b6c63b49872b4eeca49f70a8b88bb52e
Autor:
Kevin C J Yuen, Gudmundur Johannsson, Ken K Y Ho, Bradley S Miller, Ignacio Bergada, Alan D Rogol
Publikováno v:
Endocrine Connections, Vol 12, Iss 7, Pp 1-19 (2023)
Growth hormone deficiency (GHD) is a clinical syndrome that can manifest either as isolated or associated with additional pituitary hormone deficie ncies. Although diminished height velocity and short stature are useful and important clin ical marker
Externí odkaz:
https://doaj.org/article/d648e617175949ae9a9510acf8088a7a
Autor:
Elizabeth Smith, Kevin C J Yuen, Valerie Sharf, Minhwan Kim, Alissya S M Yuen, Paul R MacDonald
Publikováno v:
Stroke and Vascular Neurology, Vol 7, Iss 3 (2022)
Externí odkaz:
https://doaj.org/article/ef25bccd4d3543b9afcd15fec18e7834
Autor:
Jose M Garcia, Beverly M K Biller, Márta Korbonits, Vera Popovic, Anton Luger, Christian J Strasburger, Philippe Chanson, Ronald Swerdloff, Christina Wang, Rosa Rosanna Fleming, Fredric Cohen, Nicola Ammer, Gilbert Mueller, Nicky Kelepouris, Frank Strobl, Vlady Ostrow, Kevin C J Yuen
Publikováno v:
Endocrine Connections, Vol 10, Iss 1, Pp 76-83 (2021)
Objective: The macimorelin test is approved for the diagnosis of adult growth hormone deficiency (AGHD) based on its efficacy vs the insulin tolerance t est (ITT). Macimorelin has a significant advantage over ITT in avoiding hypoglycemia. A nalyses w
Externí odkaz:
https://doaj.org/article/cdaf660e6db34106934ef0032fb07ae0
Autor:
David R. Brown, Honey E. East, Bradley S. Eilerman, Murray B. Gordon, Elizabeth E. King, Laura A. Knecht, Brandon Salke, Susan L. Samson, Kevin C. J. Yuen, Hanford Yau
Publikováno v:
Clinical Diabetes and Endocrinology, Vol 6, Iss 1, Pp 1-13 (2020)
Abstract Background While surgery is the first-line treatment for patients with endogenous hypercortisolism (Cushing syndrome [CS]), mifepristone has been shown to be a beneficial medical treatment option, as demonstrated in the SEISMIC (Study of the
Externí odkaz:
https://doaj.org/article/ad4fd882572a4b2fad421e4c884071c0
Autor:
Kevin C. J. Yuen, Anna Camilla Birkegard, Lewis S. Blevins, David R. Clemmons, Andrew R. Hoffman, Nicky Kelepouris, Janice M. Kerr, Jens M. Tarp, Maria Fleseriu
Publikováno v:
International Journal of Endocrinology, Vol 2022 (2022)
Objective. Adult growth hormone deficiency (AGHD) is an underdiagnosed disease associated with increased morbidity and mortality. Identifying people who may benefit from growth hormone (GH) therapy can be challenging, as many AGHD symptoms resemble t
Externí odkaz:
https://doaj.org/article/393e27e69bfd4e0c9f0663801f845c60
Autor:
Jayati Chakrabarti, Ritu Pandey, Jared M. Churko, Jennifer Eschbacher, Saptarshi Mallick, Yuliang Chen, Beth Hermes, Palash Mallick, Ben N. Stansfield, Kelvin W. Pond, Curtis A. Thorne, Kevin C. J. Yuen, Andrew S. Little, Yana Zavros
Publikováno v:
Cells, Vol 11, Iss 21, p 3344 (2022)
(1) Background: Cushing’s disease (CD) is a serious endocrine disorder caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary neuroendocrine tumor (PitNET) that stimulates the adrenal glands to overproduce cortisol. Chronic exposure to
Externí odkaz:
https://doaj.org/article/654d70ac56184aceb382ca726ba56b25
Publikováno v:
Endocrinology, Diabetes & Metabolism, Vol 4, Iss 3, Pp n/a-n/a (2021)
Abstract Introduction The coronavirus disease 2019 (COVID‐19) is currently a major pandemic challenge, and cancer patients are at a heightened risk of severity and mortality from this infection. In recent years, immune checkpoint inhibitor (ICI) us
Externí odkaz:
https://doaj.org/article/a2bee772c5634adf90a4b7482d0a2ddb
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
Externí odkaz:
https://doaj.org/article/d4ff94f5659c457ea385c6900b93d6c6
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
Daily recombinant human GH (rhGH) is currently approved for use in children and adults with GH deficiency (GHD) in many countries with relatively few side-effects. Nevertheless, daily injections can be painful and distressing for some patients, often
Externí odkaz:
https://doaj.org/article/f9ec93c526184c5d8dd214e1492e1e3e